MIDATECH PHARMA PLC-ADR (MTP) 0.6728 +0.01 (+1.25%)
0.6728 +0.01 (+1.25%)
US59564R5000 - ADR
MIDATECH PHARMA PLC-ADR0.6728
NASDAQ:MTP (1/30/2023, 12:27:47 PM)+0.01 (+1.25%)
| GICS Sector | Health Care | ||
| GICS Industry | Biotechnology | ||
| Valuation | Growth | ||
| Profitability | Health | ||
| Dividend | |||
| Earnings (Last) | N/A N/A | Earnings (Next) | 04-24 2023-04-24 |
| Ins Owners | N/A | Inst Owners | 15.6% |
| Market Cap | 2.92M | Shares | 4.33M |
| PE | N/A | Fwd PE | N/A |
| Dividend Yield | N/A | Analysts | 45.71 |
| IPO | 12-08 2014-12-08 | ||
Stock Screener Links
Nasdaq Stock Screener
Find more stocks on Nasdaq
USA Stock Screener
Find more stocks on the USA
GICS Sector Stock Screener
Find competitors from the same sector on the USA
GICS Industry Stock Screener
Find competitors from the same industry on the USA
Technical Stock Screener
Find stocks with similar TA and Setup ratings on the USA
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Technical Competitors Stock Screener
Find the competitors with the best technical ratings on the USA
Best Technical Setups Competitors Stock Screener
Find the competitors with the best technical and setup ratings on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA
Company Profile
Midatech Pharma Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 20 full-time employees. The company went IPO on 2014-12-08. The firm is focused on improving the bio-delivery and biodistribution of medicines. The firm's technologies include Q-Sphera, MidaSolve and MidaCore. Q-Sphera technology focusses on long acting injectables using three-dimensional (3D) printing technology. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately 10 earlier stage programmes, which includes MTD211 (Schizophrenia, MDD), MTD219 (Prophylaxis, transplant rejection), MTX223, MTX213, MTX214, MTX110 (Glioblastoma), MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma) and MTX114 (Psoriasis).
Company Info
MIDATECH PHARMA PLC-ADR
Oddfellows Hse, 19 Newport Road
Abingdon OXFORDSHIRE CF24 0AA
P: 4401235888300.0
CEO: Stephen Stamp
Employees: 20
Website: http://www.midatechpharma.com/
MTP News
19 days ago - Bioasis Technologies Inc.Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholdersa month ago - Bioasis Technologies Inc.Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc2 months ago - Bioasis Technologies Inc.Bioasis Technologies Inc. Announces Merger with Midatech Pharma plcUS$10M Registered Direct Offering and PIPE to Strengthen Balance Sheet of Combined Company
MTP Twits
Here you can normally see the latest stock twits on MTP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
